AstraZeneca

In News

AstraZeneca pens agentic AI licensing deal with Owkin - Fierce Biotech

Fierce Biotech - May 13, 2026

How AstraZeneca Plans to Hit $80 Billion in Revenue and Expand in the U.S. - WSJ

WSJ - May 11, 2026

Innate Pharma Reports First Quarter 2026 Business Update and Financial Results - BioSpace

BioSpace - May 13, 2026

AstraZeneca says CALYPSO Phase III trial met composite primary endpoint - TipRanks

TipRanks - May 12, 2026

AstraZeneca’s $800M bet undermined by immunogenicity in phase 3 - Fierce Biotech

Fierce Biotech - May 12, 2026

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca - The National Law Review

The National Law Review - May 13, 2026

AstraZeneca stock falls after FDA panel votes against new cancer drug - CNBC

CNBC - May 01, 2026

AstraZeneca makes surprise U-turn with £300m pharma investment in UK - The Guardian

The Guardian - Apr 29, 2026

FDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on board - Fierce Biotech

Fierce Biotech - Apr 28, 2026

Eneboparatide normalised serum calcium and achieved independence from active vitamin D and oral calcium supplements in 31.1% of adults with hypoparathyroidism at week 24 in CALYPSO Phase III trial - AstraZeneca

AstraZeneca - May 12, 2026

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca - Business Wire

Business Wire - May 13, 2026

Owkin To Build AI Agents As Part Of Multi-Year K Pro License Agreement With AstraZeneca - Pulse 2.0

Pulse 2.0 - May 13, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment